CNO Financial Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CNO in the last 7 days.
CNO Financial Group's Chief Actuary, Jeremy D. Williams, sold 8,782 shares ($487,321) and acquired 7,660 shares ($168,674) via options. CNO reported Q2 2026 earnings of $1.26 per share, beating estimates, and raised its full-year profit outlook. Texas Capital Securities initiated coverage with a Buy rating and $70 target. CNO trades near its 52-week high.
CNO Financial Group (CNO) officer Jeremy Williams plans to sell 4,420 shares, valued at $244,291.63, on September 15, 2026, following a stock option exercise. The sale is under Rule 144, which governs insider stock sales.
CNO Financial Group (CNO) reported Q2 revenue beating expectations, with operating earnings per share up 45% and 16 consecutive quarters of sales growth. The stock is up 30.19% year-to-date and 42.14% over one year. However, it is slightly overvalued according to a narrative fair value of $53.50. Growth is driven by annuity and life/health policy sales, digital channels, and an aging U.S. population. Risks include low long-term interest rates and rising long-term care claims.
Recent CNO coverage spans financial news, earnings and insider activity.
In the last 30 days, CNO insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($2.6M). The most active reporter was DeToro Karen J., President, Worksite Division, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal limited confidence and could exert slight downward pressure.
A small insider sale adds modest supply to the market and may signal limited confidence from the officer.
Earnings beat may support short‑term price upside but valuation appears stretched.
Earnings miss and share decline suggest short-term downside pressure.
Potential revenue uplift from new employer groups and Medicare supplement growth.
AlphAI scores every news story that mentions CNO with an AI model for sentiment and relevance, and aggregates insider trades from CNO Financial Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CNO Financial Group's Chief Actuary, Jeremy D. Williams, sold 8,782 shares ($487,321) and acquired 7,660 shares ($168,674) via options. CNO reported Q2 2026 earnings of $1.26 per share, beating estimates, and raised its full-year profit outlook. Texas Capital Securities initiated coverage with a Buy rating and $70 target. CNO trades near its 52-week high.
2 min readCNO Financial Group (CNO) officer Jeremy Williams plans to sell 4,420 shares, valued at $244,291.63, on September 15, 2026, following a stock option exercise. The sale is under Rule 144, which governs insider stock sales.
1 min readCNO Financial Group (CNO) reported Q2 revenue beating expectations, with operating earnings per share up 45% and 16 consecutive quarters of sales growth. The stock is up 30.19% year-to-date and 42.14% over one year. However, it is slightly overvalued according to a narrative fair value of $53.50. Growth is driven by annuity and life/health policy sales, digital channels, and an aging U.S. population. Risks include low long-term interest rates and rising long-term care claims.
2 min readCNO Financial Group (CNO) fell 5.1% post-earnings, trading at $49.44. Brighthouse Financial (BHF) reported $2.10B revenue, down 2.4% YoY, missing estimates, and dropped 15.3% to $52.42. Aflac (AFL) reported $4.22B revenue, down 6.9% YoY, in line with expectations, and fell 9.4% to $114.77. The market has shifted focus from AI to geopolitics and back to fundamentals.
3 min readCNO Financial Group (CNO) is expanding in worksite and Medicare insurance markets. The company highlights growth opportunities in geographic expansion, new group development, and agent productivity. CNO has paid nearly $5 billion to policyholders through return-of-premium features. Medicare Supplement policies sold increased by over 18% annually since 2023, with in-force policies reaching 212,000 in 2026. CNO expects Medicare Supplement margins to improve to historical levels in 2026.
2 min readLinnenbringer Jeanne L. (Chief Operations Officer) sold 14,539 shares of CNO Financial Group, Inc. (CNO) at an average of $54.95 ($54.73–$55.11, $0.80M total) across 4 trades over 2026-08-31 to 2026-09-02 under a Rule 10b5-1 trading plan.
1 min readDeToro Karen J. (President, Worksite Division) sold 24,674 shares of CNO Financial Group, Inc. (CNO) at an average of $54.92 ($54.73–$55.12, $1.36M total) across 5 trades over 2026-08-31 to 2026-09-02 under a Rule 10b5-1 trading plan.
1 min readCNO Financial Group (CNO) disclosed that officer Karen DeToro plans to sell 9,336 shares of CNO common stock, valued at $511,002.96 as of September 1, 2026. The planned sales include 1,836 restricted shares and 7,500 shares from a stock option exercise. DeToro also reported a prior sale of 9,374 shares on August 31, 2026 for $515,366.21.
1 min readCNO Financial Group reports 18% CAGR growth in worksite sales since 2020, driven by agent productivity and expansion. Medicare Supplement sales also rising, with strong persistency and market share potential. Growth supported by exclusive distribution and high-touch service, according to the company.
1 min readCalifornia Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.
6 min read
